Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Australian (ASX) Biotech Industry Analysis

UpdatedAug 25, 2026
DataAggregated Company Financials
Companies33
  • 7D20.9%
  • 3M63.0%
  • 1Y-20.0%
  • YTD-1.4%

In the last week, the Biotech industry is up 21%, with CSL up 10%. In the past year, the industry is down 20%. Earnings are forecast to grow by 42% annually.

Industry Valuation and Performance

Has the Australian Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 25 Aug 2026AU$94.4bAU$23.7b-AU$4,092,652,617.6733.5x-23.1x4x
Thu, 23 Jul 2026AU$68.9bAU$23.6bAU$1.4b21.8x47.8x2.9x
Sat, 20 Jun 2026AU$67.7bAU$23.5bAU$1.4b22x47x2.9x
Mon, 18 May 2026AU$59.6bAU$23.1bAU$1.4b19.5x42.6x2.6x
Wed, 15 Apr 2026AU$78.1bAU$23.2bAU$1.4b23.9x55.5x3.4x
Fri, 13 Mar 2026AU$79.1bAU$23.1bAU$1.4b25.2x56.4x3.4x
Sun, 08 Feb 2026AU$97.6bAU$23.4bAU$3.8b20.3x25.6x4.2x
Tue, 06 Jan 2026AU$95.5bAU$24.6bAU$4.0b18.5x23.8x3.9x
Thu, 04 Dec 2025AU$100.6bAU$24.9bAU$4.1b19.3x24.7x4x
Sat, 01 Nov 2025AU$99.4bAU$25.1bAU$4.1b18.8x24.2x4x
Mon, 29 Sep 2025AU$106.1bAU$25.1bAU$4.1b20.5x25.8x4.2x
Wed, 27 Aug 2025AU$117.3bAU$25.3bAU$4.2b34.4x27.7x4.6x
Fri, 25 Jul 2025AU$144.6bAU$24.1bAU$3.8b47.9x38.1x6x
Sun, 22 Jun 2025AU$130.0bAU$24.5bAU$3.9b20x33.6x5.3x
Tue, 20 May 2025AU$131.3bAU$24.7bAU$3.9b20.6x33.7x5.3x
Thu, 17 Apr 2025AU$130.9bAU$24.9bAU$3.9b20.5x33.2x5.2x
Sat, 15 Mar 2025AU$135.8bAU$25.2bAU$4.0b21.3x34x5.4x
Mon, 10 Feb 2025AU$148.1bAU$24.5bAU$3.7b24.2x40.4x6x
Wed, 08 Jan 2025AU$153.8bAU$24.5bAU$3.7b24.7x42x6.3x
Fri, 06 Dec 2024AU$150.4bAU$23.9bAU$3.6b25.8x42.2x6.3x
Sun, 03 Nov 2024AU$148.7bAU$23.5bAU$3.5b26.5x42.6x6.3x
Tue, 01 Oct 2024AU$150.6bAU$22.3bAU$3.3b28x45.8x6.8x
Thu, 29 Aug 2024AU$159.8bAU$22.7bAU$3.4b30.7x46.4x7x
Sat, 27 Jul 2024AU$160.3bAU$22.5bAU$3.3b32.2x48.5x7.1x
Mon, 24 Jun 2024AU$153.1bAU$22.2bAU$3.3b31.8x47x6.9x
Wed, 22 May 2024AU$144.1bAU$22.0bAU$3.2b30.9x44.8x6.5x
Fri, 19 Apr 2024AU$140.0bAU$22.9bAU$3.4b29.7x41.7x6.1x
Sun, 17 Mar 2024AU$143.3bAU$22.4bAU$3.3b30.5x43.7x6.4x
Tue, 13 Feb 2024AU$147.7bAU$21.0bAU$2.9b33.7x51.6x7x
Thu, 11 Jan 2024AU$148.3bAU$20.5bAU$2.7b34.9x54.8x7.2x
Sat, 09 Dec 2023AU$135.8bAU$20.8bAU$2.8b33.8x49.3x6.5x
Mon, 06 Nov 2023AU$124.1bAU$21.1bAU$2.8b30x44.2x5.9x
Wed, 04 Oct 2023AU$126.5bAU$21.6bAU$2.8b29x44.6x5.9x
Fri, 01 Sep 2023AU$140.0bAU$21.3bAU$2.6b34.9x54.3x6.6x
Price to Earnings Ratio

54.3x


Total Market Cap: AU$140.0bTotal Earnings: AU$2.6bTotal Revenue: AU$21.3bTotal Market Cap vs Earnings and Revenue0%0%0%
Australian Biotech Industry Price to Earnings3Y Average 41.2x202420252026
Current Industry PE
  • Investors are pessimistic on the Australian Biotechs industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The 3-year average PS ratio of 5.4x is higher than the industry's current PS ratio of 4.0x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Meanwhile revenues have grown 3.7% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Trends

Which industries have driven the changes within the Australian Healthcare industry?

AU Market0.24%
Healthcare9.50%
Biotech20.87%
Biotech20.87%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
CSL CSLAU$173.6410.0%
+AU$7.6b		-19.3%PS3.8x
TTX TetratherixAU$6.7411.6%
+AU$37.1m		61.2%PS92.6x
PAR Paradigm BiopharmaceuticalsAU$0.2325.0%
+AU$26.7m		-22.4%PS15816.1x
CUV Clinuvel PharmaceuticalsAU$10.602.3%
+AU$12.1m		-22.6%PE16.4x
DXB DimerixAU$0.326.8%
+AU$12.0m		-33.0%PS25.5x

Latest News

PTX
AU$0.067
Prescient Therapeutics
7D
-16.3%
1Y
55.8%
MSB
AU$2.35
Mesoblast
7D
-2.1%
1Y
-4.5%
TTX
AU$6.74
Tetratherix
7D
11.6%
1Y
61.2%
COV
AU$0.35
Cleo Diagnostics
7D
7.6%
1Y
-1.4%
TLX
AU$16.16
Telix Pharmaceuticals
7D
-3.6%
1Y
-14.6%
RAD
AU$0.011
Radiopharm Theranostics
7D
-12.5%
1Y
-61.1%
CSL
AU$173.64
CSL
7D
10.0%
1Y
-19.3%
Narrative Update • Aug 20

CSL: Roofing Restructuring And Owens Corning Optionality Will Shape Earnings Path

Analysts have lifted their fair value estimate for Carlisle (CSL) to A$163.95 from A$138.19, reflecting updated assumptions on the discount rate, slightly higher profit margins and a higher future P/E multiple. They are also factoring in recent research that adjusts expectations around roofing demand, input costs and potential Owens Corning deal scenarios.
CUV
AU$10.60
Clinuvel Pharmaceuticals
7D
2.3%
1Y
-22.6%
ATH
AU$0.51
Alterity Therapeutics
7D
2.0%
1Y
-15.0%
ATX
AU$0.14
Amplia Therapeutics
7D
-6.5%
1Y
-23.7%
PYC
AU$2.08
PYC Therapeutics
7D
-2.8%
1Y
60.0%
ARX
AU$0.56
Aroa Biosurgery
7D
-2.6%
1Y
-7.4%
OCC
AU$0.78
Orthocell
7D
-2.5%
1Y
-35.1%
PAR
AU$0.23
Paradigm Biopharmaceuticals
7D
25.0%
1Y
-22.4%
DXB
AU$0.32
Dimerix
7D
6.8%
1Y
-33.0%
NOX
AU$0.095
Noxopharm
7D
18.8%
1Y
-13.6%